Nielsen, D.L., et al.
http://www.thebreastonline.com/article/PIIS0960977612001944/abstract?rss=yes
Therapies targeting the human epidermal growth factor receptor (HER) 2 are effective in metastatic breast cancer (MBC). We review the efficacy of HER2-directed therapies, focussing on monoclonal antibodies and tyrosine kinase inhibitors targeting HER2 that have been tested in phase II–III studies in MBC.
